Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
Dr. Yu Cao, Dr. David T. Rodgers, Dr. Juanjuan Du, Insha Ahmad, Eric N. Hampton, Dr. Jennifer S. Y. Ma, Dr. Magdalena Mazagova, Dr. Sei-hyun Choi, Dr. Hwa Young Yun, Dr. Han Xiao, Dr. Pengyu Yang, Xiaozhou Luo, Dr. Reyna K. V. Lim, Holly M. Pugh, Dr. Feng Wang, Dr. Stephanie A. Kazane, Dr. Timothy M. Wright, Dr. Chan Hyuk Kim, Prof. Peter G. Schultz and Dr. Travis S. Young
Article first published online: 4 MAY 2016 | DOI: 10.1002/anie.201601902
CAR-T control: Chimeric antigen receptor T (CAR-T) cells were engineered to be controlled by exogenous switch molecules. Site-specific incorporation of the small molecule FITC or a short peptide neo-epitope in the anti-Her2 4D5 Fab allowed activation of corresponding switchable CAR-T cells towards Her2-expressing solid tumor cells, and displayed significant anti-cancer effects both in vitro and in vivo.